Larimar Submits First BLA Module for Friedreich’s Ataxia Drug Nomlabofusp — Larimar Therapeutics, Inc.

Event summary

Larimar Therapeutics submitted the first module of its rolling Biologics License Application (BLA) for nomlabofusp, targeting accelerated approval for Friedreich’s ataxia.
Positive open-label data showed sustained skin FXN levels and directional improvements in clinical outcomes compared to a natural history reference population.
One non-ambulatory patient became ambulatory after one year of treatment, with no ambulatory patients progressing to non-ambulatory status.
The FDA confirmed the existing data package appears sufficient for BLA submission seeking accelerated approval based on skin FXN as a potential novel surrogate endpoint.

The big picture

Larimar Therapeutics is advancing its lead candidate, nomlabofusp, through a critical regulatory milestone with the submission of the first BLA module. The positive open-label data and FDA alignment on the surrogate endpoint highlight the potential for nomlabofusp to become the first disease-modifying therapy for Friedreich’s ataxia, a rare and progressive neurological disorder. This development underscores the growing focus on targeted treatments for complex rare diseases and the strategic importance of regulatory pathways for accelerating drug approvals.

What we're watching

Regulatory Pathway: Whether the FDA will accept skin FXN as a surrogate endpoint for accelerated approval and the timeline for reviewing the remaining BLA modules.
Clinical Efficacy: The sustained clinical benefits of nomlabofusp in long-term treatment and whether these results translate into the global confirmatory Phase 3 study.
Market Potential: The pace at which Larimar can commercialize nomlabofusp if approved, given the significant unmet medical need for Friedreich’s ataxia treatments.